Abciximab: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Abciximab" ([Edit=Allow only autoconfirmed users] (expires 19:17, 12 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 19:17, 12 February 2014 (UTC))))
mNo edit summary
Line 1: Line 1:
<small>'''''Synonyms:'''''  7E3 antibody, ReoPro, abciximab, c7E3</small>
__NOTOC__
 
{{XXXXX}}
{{CMG}}
{{CMG}}


==Dosing and Administration==
'''''For patient information, click <u>[[XXXXX (patient information)|here]]'''''</u>.
The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of PCI, followed by a continuous intravenous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.


Patients with unstable angina not responding to conventional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10 µg/min, concluding one hour after the PCI.
==Overview==


==[[Abciximab indications|Indications]]==


==[[Abciximab contraindications|Contraindications]]==


==[[Abciximab side effects|Side effects]]==
==Category==


==[[Abciximab drug interactions|Drug interactions]]==


==[[Abciximab precautions|Precautions]]==


==[[Abciximab instructions for administration|Instructions for administration]]==
==US Brand Names==


==[[Abciximab pharmacokinetics|Pharmacokinetics]]==


==[[Abciximab how supplied|How supplied]]==


==[[Abciximab (patient information)|Patient information]]==
==FDA Package Insert==


==[http://www.drugbank.ca/drugBank/drugStructureFile/drug_files/fda_labels/DB00054.pdf  FDA package label]==
''' [[XXXXX indications and usage|Indications and Usage]]'''
'''| [[XXXXX dosage and administration|Dosage and Administration]]'''
'''| [[XXXXX dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[XXXXX contraindications|Contraindications]]'''
'''| [[XXXXX warnings|Warnings and Precautions]]'''
'''| [[XXXXX adverse reactions|Adverse Reactions]]'''
'''| [[XXXXX drug interactions|Drug Interactions]]'''
'''| [[XXXXX use in specific populations|Use in Specific Populations]]'''
'''| [[XXXXX overdosage|Overdosage]]'''
'''| [[XXXXX description|Description]]'''
'''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]'''
'''| [[XXXXX nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[XXXXX clinical studies|Clinical Studies]]'''
'''| [[XXXXX how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[XXXXX patient counseling information|Patient Counseling Information]]'''
'''| [[XXXXX labels and packages|Labels and Packages]]'''


==[[Abciximab detailed information|Detailed information]]==
==Mechanism of Action==


==[http://www.abciximab.com Official website]==


[[es:Abciximab]]
[[pt:Abciximab]]
{{FDA}}


==References==


{{Reflist|2}}


[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 19:22, 29 January 2014


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here.

Overview

Category

US Brand Names

FDA Package Insert

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Abciximab&oldid=935399"